Insmed Investor Presentation - ARIKAYCE and Pipeline

Insmed is a biopharmaceutical company focused on the development and commercialization of ARIKAYCE for nontuberculous mycobacteria (NTM) lung disease. The presentation outlines the company's approved product ARIKAYCE and pipeline candidates including brensocatib and TPIP, along with associated regulatory, commercial and financial risks.